Cinven's CCM Pharma seeks 75bp margin cut
CCM Pharma has fixed the deadline for early bird commitments to a debt repricing, as it seeks to reduce margins on its loans by as much as 75bp.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast